The abstract is read at the publisher; the summary is JClub's.
High-sensitivity HLA-A2-restricted TCR-T cells, unlike low-sensitivity counterparts, mediated durable tumor regression in an HLA-A2-transgenic syngeneic mouse melanoma model.
- Why it matters: Adoptive T cell therapy often fails in solid tumors, and it is unclear how TCR properties and host-cell antigen presentation jointly shape treatment outcome.
- What they did: In an HLA-A2-transgenic syngeneic mouse cancer model, TCR-engineered T cells with different antigen sensitivities were tested against the same melanoma antigen, including cross-presentation by tumor-associated CD11b+ myeloid cells.
- The result: Durable control with high-sensitivity TCR-T cells correlated with stronger recognition of cross-presented antigen on CD11b+ myeloid cells, higher intratumoral effector activity, and tumor IFN-γ levels that matched peripheral blood and therapeutic response.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.